At Read My Lips Boston, a pop-up bookshop, sisters Hannah and Lily Barrett showcase romance books with diverse protagonists.

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Follow-up results from the phase 3 EMBER-3 study showed that, as a monotherapy, Inluriyo demonstrated a 38% reduction in the ...

The study showed benefits beyond survival, including slower disease progression in certain patient groups. ・Combining the ...

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care.